Introduction
Tracheobronchomalacia (TBM) occurs due to the degeneration of cartilaginous tissue and elastic fibers of the main respiratory tract. The diameters of dynamic airways decrease by 50% because of the excessive collapse of the trachea and bronchi during expiration (1, 2) . Dynamic airway collapse and TBM are different diseases but both may be present in the same patient group (3) . Its prevalence in adults is unknown. TBM was found in 12% of patients who had bronchoscopies performed due to respiratory pathologies (4, 5) , in 23% of COPD patients, and in 44% of patients with chronic bronchitis (6) .
Dynamic airway obstruction and air trapping may occur with TBM. Except for the asymptomatic course, TBM may also be confused with asthma or COPD; therefore, a diagnosis cannot be established for all cases (1, 7) . However, according to several extensive studies that were conducted on the general population, the incidence of TBM is thought to be 5%-10% (5, 8) .
TBM is a dynamic condition; therefore, radiography cannot be routinely used as a diagnostic method. Computerized tomography and real-time spatialresolution three-dimensional reconstructions, especially with a multidetector scanner, are ideal methods in noninvasive scanning (9, 10) . Bronchoscopy is the gold standard for defining dynamic airway collapse (1, 3) .
Although treatment is not necessary in patients who are asymptomatic, determining the patients who are in need of treatment is difficult. There is no specific approach for TBM treatment (11, 12) . After treating symptoms of the underlying pathology, continuous positive airway pressure (CPAP) may be used, which functions as a pneumatic stent that prevents the airway from collapsing (13) . Silicone stents may be used for stabilizing the airway as an alternative treatment method (10, 11, 14) . Fibrous cicatrix formation and membrane stabilization can be achieved via devascularization and coagulation of tissues with yttrium aluminum garnet (YAG) laser treatment (15) . For localized TBM cases, surgical techniques other than segmental tracheal resection may be performed to strengthen the cartilage wall or stabilize the posterior membrane (16, 17) . In TBM treatment, as an interventional bronchoscopic method, stents improve symptoms and respiratory function by restoring the diameter of the airways. In our study, we retrospectively analyzed which interventional bronchoscopic method could be used to provide airway stabilization and gain control of symptoms and for whom this method could be used.
Materials and methods

Patients
We analyzed the records of 944 patients who underwent rigid bronchoscopies under general anesthesia in our interventional pulmonology unit between January 2005 and January 2013. Of these 944 patients, 15 patients had TBM and underwent bronchoscopic treatment. These patients were retrospectively investigated. Thirteen of the patients with TBM had dyspnea as a cardinal symptom. The patients underwent physical examinations and radiologic and laboratory tests were undertaken. The anesthesia department was consulted for rigid bronchoscopies that were performed under general anesthesia and preoperative preparations were completed. The patients gave informed consent for the procedures.
Methods
All the patients were intubated using a rigid bronchoscope (Efer Endoscopy, La Ciotat, France) under intravenous general anesthesia using standard techniques and mechanical debridement was performed when necessary.
Laser
Diode laser or argon plasma coagulation (APC) was used during endobronchial treatment. A diode laser was used for the endobronchial treatment at a wavelength of 980 nm with 4 to 25 W pulsed mode (Ceralas D 25; Biolitec, Germany). APC (40 W, blended mode-continuous flow) was performed using a device manufactured by ERBE Elektromedizine GBMH (Germany). Standardized protocols for appropriate power selections were used in accordance with the manufacturer's recommendations.
Cryotherapy
Cryotherapy was performed using the ERBOKRYO system (Elektromedizine GBMH) when necessary over the granulation tissue.
We evaluated procedural techniques, stent duration, complications, and long-term treatment success. This is a retrospective data analysis. No ethical statement is needed in Turkey for studies in which there is a retrospective analysis of standard diagnostic data.
Data were collected and analyzed by descriptive and inferential statistics using MedCalc statistical software (MedCalc 12.1; MedCalc Software, Belgium).
Results
Ten of our 15 patients were men and the mean age was 65.07 ± 13.19 years. Nine of the patients were smokers. Thirteen patients (86.6%) had some comorbid diseases (Table 1) .
Fiber-optic bronchoscopy was used once in 5 patients, twice in 3 patients, and four times in 1 patient in our patient follow-ups. The number of patients who required further rigid bronchoscopy under general anesthesia and the time (days) between procedures are shown in Table 2 . The extensiveness and localization of TBM is shown in Table 3 . In attempts for treatment relative to the extent and locality of TBM, Y-stents were used in 4 patients ( Figure 1) ; silicon stents were used in the trachea of 4 patients; a silicon stent was used in the left main bronchus of 1 patient; a silicon stent was used in the right main bronchus of 1 patient; and no endobronchial treatment was used for 5 patients. Posttreatment complications and their severities are given in Table 4 . Stents were removed in 2 patients during follow-ups due to early migration. Stents were removed in 5 of the 7 patients due to frequent obstructions of the stent caused by recurrent severe mucostasis (Figure 2 ). To provide coagulation to the tracheal posterior wall and membrane stabilization, APC was performed in 1 patient. Cryotherapy was used in 1 patient on the granulation tissue that was formed in the distal segment of the stent. A stent could not be used in 1 patient whose longitudinal width was 45 mm because of the absence of adequately sized stents. Patients who underwent endobronchial treatment procedures were followed up in the intensive care unit (Table 2) . Follow-up durations of patients whose stents were removed for various reasons are given in Table 5 . Stents were not removed for the purpose of TBM treatment in 2 patients. No frequent admissions due to COPD exacerbation and respiratory distress to emergency rooms and hospitalizations were observed during the follow-up time of these patients (1141 and 849 days).
One patient with a long-term stent who had no problems during follow-up died from a nonpulmonary cause. One patient is still under follow-up. 
Discussion
Determining the need for treatment in TBM patients and lack of a distinctive treatment approach makes treatment management more difficult. As mentioned before, previous studies have reported the results of the different treatment approaches for these patients. We evaluated 15 patients with TBM in our series in terms of treatment and reviewed the success rate of procedures with postprocedure followups. After application of stents, only two patients had longterm follow-ups due to complications of the procedures, such as mucostasis, migration, and granulation. In patients who were at risk before TBM surgery, endobronchial treatment methods can be used as a tool for reducing symptoms and finding the right treatment modality. There is a need for studies that include large numbers of patients to show a high rate of success in selected cases. CPAP is a noninvasive method that prevents airway collapse, which may be considered after the symptoms of TBM and concomitant conditions have been managed. It reduces airway resistance and the energy spent on respiration by keeping the airways open with positive pressure. It is a method that can be both intermittently and continuously used in patients who have mild symptoms and who cannot be treated invasively. Surgical techniques other than segmental tracheal resection may be performed in patients with localized TBM to strengthen cartilage walls or stabilize the posterior membrane. Considering major and minor surgical complications, significant improvements can be made with symptoms, respiratory parameters, and quality of life. While there is no standard of care in the treatment of TBM, silicon stent application appears to be a good treatment for selected patients. Laser coagulation has also shown the same success rate. In patients who have COPD, asthma, or respiratory distress, procedures should be performed while considering high risks and bronchoscopic treatment criteria.
Ernst et al. prospectively investigated 75 patients in their study and observed that neither the respiratory function tests nor the 6-min walk test parameters showed significant improvement at the end of the first month, although there were significant improvements in terms of symptoms and quality of life (10, 11) . In our study, the number of presentations to emergency rooms and hospitalizations due to respiratory distress of patients who had permanent stents were significantly reduced; however, there were a limited number of patients.
YAG lasers reach into the connective tissue and submucosa and help fibrous cicatrix formation and posterior membrane stabilization. Promising results were achieved in a study conducted in Marseilles with diffuse collapse or localized collapse in posterior side (18) . Prospective studies are needed to confirm the treatment efficacy of YAG laser treatment.
Stents are another method of treatment; however, there is no ideal stent available for airway stabilization in invasive bronchoscopy. There are two types of stent: metallic and silicon. Stents fix the diameters of airways. The use of silicon stents improves the clinical symptoms of TBM (19, 20) . Constant change in airway diameters in TBM increases the risk of migration with silicon stents and fracture with metallic stents. With both stent types there is an increased risk of granuloma and mucus plug formation at both ends of the stents and places where there is contact with mucosa. Stents should be used in patients who have severe symptoms, whose treatment-related complications can be predicted, and who can be followed up with frequent bronchoscopies. This treatment has inadequacies, such as mucostasis formation at the distal segment of the stent and stent migration (21, 22) . Mucostasis, migration, and granulation tissue formation prompted stent removal in most of the patients in our study and this shows the need for large studies that include large numbers of participants.
In selected cases with TBM and dynamic airway collapse, silicon stents appear to be the ideal treatment method. Bronchoscopic procedures in selected patients should be undertaken by experienced centers because diagnosing TBM is difficult and patients who present are in respiratory distress. Stents are used as a treatment test in patients with severe symptoms who are candidates for surgery to identify the benefits of fixing the airway diameter and stabilization. Stents can be used as a long-term palliative treatment in patients who have no other treatment alternative if they provide significant symptomatic improvement, provided that stent follow-up and care are periodically undertaken.
